Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Adenocarcinoma Clinical Trials

A listing of Adenocarcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (4) clinical trials

Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate

Radiation therapy is an effective and frequently utilized modality for the treatment of clinically localized prostate cancer. Traditionally, external beam radiation has been delivered in a fractionated manner using daily doses of 1.8-2.0 Gy. This daily dose was derived from early animal experiments and clinical experience, supported by mathematical models ...

Phase

Prostate Adenocarcinoma TransCutaneous Hormones

OBJECTIVES Primary Compare the progression-free survival and overall survival of patients with locally advanced or metastatic prostate cancer treated with transcutaneous estrogen patches vs luteinizing hormone-releasing hormone analogues. Secondary Compare the cardiovascular system-related morbidity and mortality in patients treated with these regimens Compare the activity of these treatments, in terms ...

Phase

Safety and Efficacy of Radiotherapy Combined With a 6-month LH-RH Agonist and Abiraterone Hormone Therapy Treatment in Biochemically-relapsing Prostate Cancer Following Surgery

As there is no prospective data on the combination of abiraterone and salvage radiotherapy, the aim of this study is to further evaluate the safety profile of abiraterone acetate plus prednisone in patients with prostate cancer who are biochemically relapsing after surgery and undergo salvage radiotherapy with 6-months LH-RH agonist. ...

Phase

Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy

Enzalutamide is a second-generation androgen receptor signaling inhibitor that significantly prolongs survival in patients with metastatic castration-resistant prostate cancer who have received prior docetaxel chemotherapy 35,36. Enzalutamide has demonstrated activity in cells that overexpress the androgen receptor. Unlike previous androgen receptor blocker (ARB) agents, Enzalutamide does not display any agonist ...

Phase